JKN 2301
Alternative Names: JKN-2301Latest Information Update: 17 Feb 2026
At a glance
- Originator Joincare Pharmaceutical
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 07 Nov 2025 Phase-III clinical trials in Influenza virus infections (In children) in China (PO) (NCT07357051)